Grove Bank & Trust’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $933K | Sell |
1,861
-20
| -1% | -$9.6K | 0.09% | 120 |
|
|
2026
Q1 | $925K | Buy |
1,881
+98
| +5% | +$53.2K | 0.1% | 118 |
|
|
2025
Q4 | $1.03M | Buy |
1,783
+503
| +39% | +$284K | 0.12% | 112 |
|
|
2025
Q3 | $621K | Sell |
1,280
-4,693
| -79% | -$2.18M | 0.07% | 151 |
|
|
2025
Q2 | $2.42M | Sell |
5,973
-317
| -5% | -$133K | 0.3% | 66 |
|
|
2025
Q1 | $3.13M | Buy |
6,290
+132
| +2% | +$71.5K | 0.42% | 54 |
|
|
2024
Q4 | $3.2M | Buy |
6,158
+66
| +1% | +$36.3K | 0.44% | 48 |
|
|
2024
Q3 | $3.77M | Buy |
6,092
+187
| +3% | +$111K | 0.56% | 41 |
|
|
2024
Q2 | $3.27M | Buy |
5,905
+250
| +4% | +$143K | 0.52% | 40 |
|
|
2024
Q1 | $3.29M | Buy |
5,655
+2,107
| +59% | +$1.18M | 0.55% | 43 |
|
|
2023
Q4 | $1.88M | Buy |
3,548
+70
| +2% | +$33.9K | 0.35% | 57 |
|
|
2023
Q3 | $1.76M | Buy |
3,478
+316
| +10% | +$168K | 0.36% | 57 |
|
|
2023
Q2 | $1.65M | Buy |
3,162
+91
| +3% | +$49.1K | 0.33% | 58 |
|
|
2023
Q1 | $1.77M | Buy |
3,071
+37
| +1% | +$20.9K | 0.37% | 55 |
|
|
2022
Q4 | $1.67M | Buy |
3,034
+1,813
| +148% | +$961K | 0.37% | 58 |
|
|
2022
Q3 | $619K | Hold |
1,221
| – | – | 0.15% | 116 |
|
|
2022
Q2 | $663K | Hold |
1,221
| – | – | 0.16% | 112 |
|
|
2022
Q1 | $721K | Buy |
1,221
+93
| +8% | +$53.4K | 0.14% | 126 |
|
|
2021
Q4 | $753K | Hold |
1,128
| – | – | 0.14% | 124 |
|
|
2021
Q3 | $644K | Hold |
1,128
| – | – | 0.14% | 127 |
|
|
2021
Q2 | $569K | Sell |
1,128
-4
| -0.4% | -$1.89K | 0.12% | 129 |
|
|
2021
Q1 | $517K | Sell |
1,132
-7
| -0.6% | -$3.34K | 0.12% | 135 |
|
|
2020
Q4 | $531K | Buy |
1,139
+159
| +16% | +$74.6K | 0.14% | 125 |
|
|
2020
Q3 | $433K | Buy |
980
+93
| +10% | +$38.4K | 0.13% | 129 |
|
|
2020
Q2 | $321K | Buy |
887
+94
| +12% | +$31.5K | 0.11% | 146 |
|
|
2020
Q1 | $225K | Sell |
793
-349
| -31% | -$110K | 0.09% | 153 |
|
|
2019
Q4 | $371K | Sell |
1,142
-5
| -0.4% | -$1.52K | 0.11% | 140 |
|
|
2019
Q3 | $334K | Buy |
1,147
+306
| +36% | +$87.6K | 0.11% | 144 |
|
|
2019
Q2 | $247K | Buy |
841
+26
| +3% | +$7.16K | 0.09% | 150 |
|
|
2019
Q1 | $223K | Buy |
+815
| New | +$203K | 0.09% | 153 |
|
|
2018
Q1 | – | Sell |
-755
| Closed | -$143K | – | 433 |
|
|
2017
Q4 | $143K | Sell |
755
-345
| -31% | -$66.1K | 0.06% | 194 |
|
|
2017
Q3 | $208K | Buy |
1,100
+240
| +28% | +$43.5K | 0.1% | 153 |
|
|
2017
Q2 | $150K | Buy |
860
+143
| +20% | +$24K | 0.1% | 159 |
|
|
2017
Q1 | $110K | Sell |
717
-950
| -57% | -$145K | 0.09% | 156 |
|
|
2016
Q4 | $235K | Buy |
1,667
+72
| +5% | +$10.6K | 0.18% | 97 |
|
|
2016
Q3 | $254K | Buy |
1,595
+600
| +60% | +$92.5K | 0.22% | 88 |
|
|
2016
Q2 | $147K | Hold |
995
| – | – | 0.13% | 105 |
|
|
2016
Q1 | $141K | Hold |
995
| – | – | 0.13% | 106 |
|
|
2015
Q4 | $141K | Buy |
+995
| New | +$133K | 0.13% | 112 |
|
Other funds holding TMO
LT
CF
SP
DLA
PL
Grove Bank & Trust's TMO Position: Q2 2026 in Review
Grove Bank & Trust reduced its Thermo Fisher Scientific (TMO) stake by 1.1% in Q2 2026, selling an estimated $9.6K and leaving 1,861 shares worth $933K. The position accounts for 0.09% of the portfolio, ranked #120.
Grove Bank & Trust first reported a position in TMO in Q4 2015 and has held it in 39 quarters since. The position peaked at $3.77M in Q3 2024. 623 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Grove Bank & Trust held 1,861 shares of Thermo Fisher Scientific worth $933K as of Q2 2026.
- Grove Bank & Trust sold 20 Thermo Fisher Scientific shares in Q2 2026, an estimated $9.6K.
- Thermo Fisher Scientific made up 0.09% of Grove Bank & Trust's portfolio in Q2 2026, its #120 holding.
- Grove Bank & Trust first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 39 quarters since.
- Grove Bank & Trust's Thermo Fisher Scientific position peaked at $3.77M in Q3 2024.
- 623 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.